Indian drugmakers likely to stay competitive despite planned tariffs, Dr Reddy's says

Indian drugmakers, including Dr Reddy's, are confident about maintaining competitiveness in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports. Dr Reddy's MD, GV Prasad, stated that Indian firms are awaiting more details on the tariffs but emphasized that shifting pharmaceutical production to the U.S. is impractical and would increase costs, keeping Indian and Chinese companies competitive.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pQOl4yq
via IFTTT